I provide below a schedule for the upcoming InnovationWell and eCheminfo Community of Practice meetings at Bryn Mawr.
I also include a location map here which may be useful upon arrival:
Download bryn_mawr_campus_map_douglas_connect_meeting.pdf
[Please follow continuation here to view schedule.]
This year's InnovationWell Autumn Community of Practice Meeting will take place 14-17 October 2008 at Bryn Mawr College, Bryn Mawr, Philadelphia, USA to discuss the following areas of Innovation in Life Science & Healthcare R&D:
Critical Path Advances in Drug Development, Innovation & Knowledge Management in R&D and Translational Medicine, Computational Biology, Predictive ADME, Predictive Toxicology, Metabolomics, Biomarkers, Systems Biology
Program Summary
Systems Biology, chaired by Keith Elliston (Genstruct)
Computational Biology, chaired by Debraj Guhathakurta (Merck)
Knowledge Management in Translational Medicine, David Bousfield (Ganesha Associates)
Applications of Metabolomics to Drug Discovery & Development, chaired by Bruce Kristal (Brigham and Women's Hospital)
Predictive ADME, chaired by Anthony E. Klon (Pharmacopeia Drug Discovery)
Predictive Toxicology, chaired by Artem Cherkasov (University of British Columbia)
Pre-Conference Workshop, 13 October 2008
Knowledge Management in R&D
chaired by John Conway (Accelrys) and Frank Hollinger (FRESH Directions Consulting)
Speakers
Keith Elliston (Genstruct), Debraj GuhaThakurta (Rosetta Inpharmatics, Merck & Co.), Stephen W. Edwards (U.S. Environmental Protection Agency), Paul McDonagh (Gene Network Sciences), Christopher M.L.S. Bouton (Pfizer), James R. Brown (GlaxoSmithKline), John Wilbanks (Creative Commons), Barry Bunin (Collaborative Drug Discovery), Michael Liebman (Windber Research Institute), Jerry Wright (Johns Hopkins Medical Institutions), Anastasia Christianson (AstraZeneca), James Golden (Science Applications International Corporation), John Speakman (National Cancer Institute), William Hayes (Biogen Idec), Andrew McMurry (Harvard Medical School), Eugene Clark (Partners Healthcare), Alvin Berger (Metabolon), John Newman (USDA), Bruce Kristal (Brigham and Women's Hospital), Anton Hopfinger (University of New Mexico), Heidi Einolf (Novartis), Yojiro Sakiyama (Pfizer), Olga Obrezanova (BioFocus DPI, UK), Anthony E. Klon (Pharmacopeia), Artem Cherkasov (University of British Columbia, Canada), Ann Richards (US EPA), Curt Breneman (RPI), Alex Tropsha (UNC), Barry Hardy (Douglas Connect), Weida Tong (FDA)
CFP
We invite contributed papers from members of academic, government research and commercial organizations on areas of new research and innovation relevant to innovation and knowledge management in the life sciences. The work presented should involve innovative new method development or application in the areas of systems biology, translational medicine, knowledge management, computational biology, metabolomics, predictive ADME, predictive toxicology or bioinformatics. Studies including experimental work in medicinal chemistry, screening, experimental toxicology, pre-clinical evaluation, lead optimisation and translational medicine are welcome.
Abstracts (300-500 words) should be submitted to innovationwell -[at]-douglasconnect.com by 31 July 2008, and be accompanied by a short biography of the presenting author (300-500 words). Abstracts approved by the scientific organizing committee will be selected for scheduling on the conference program and in meeting poster sessions. Authors will be notified of acceptance as soon as a review of submitted materials takes place and at the latest by 15 August 2008.
Bursary
Bursary Awards will be used to support the attendance of a selection of academic young investigators at the meeting and workshops. Applicants should be working in a relevant area of research related to life science, healthcare, and drug product discovery and development at the postdoctoral, graduate student and senior undergraduate levels.
To apply for the bursary please send an email with a) your abstract and biography (300-500 words each), b) your CV of 1-2 pages, c) a short description of your interests and career motivations related to R&D (300-500 words) to innovationwell -[at]- douglasconnect.com by 31 July 2008. The recipients of the bursary awards will be selected based on an evaluation of the quality and innovation of the described research and the potential positive impact of attendance at the meeting on their research and career progress. Authors will be notified of acceptance by 15 August 2008.
Poster Session
All InterAction Meeting registrants are eligible to present a Conference Poster. The Poster Sessions will take place in the evenings in Thomas Great Hall on campus, where refreshments and dinner are also served. Poster Abstracts (300-500 words) with Title, Institution, Authors and Contact Information should be submitted to barry.hardy -[at]-
douglasconnect.com Abstracts will be considered based on date of submission and quality, and will be reviewed and accepted as they are received. To be considered for the formal program, they should be submitted at the very latest by 31 August 2008.
Download Program Brochure as pdf:
Download InnovationWell-BM08-Final1.pdf
Contact:
Program: Dr. Barry Hardy, InnovationWell Community of Practice, Douglas Connect. Tel: +41 61 851 0170. barry.hardy -[at]- douglasconnect.com
Registration Enquiries: Nicki Douglas, Douglas Connect, Baermeggenweg 14, 4314 Zeiningen, Switzerland. Tel: +41 61 851 0461. InnovationWell -[at]- douglasconnect.com or please visit:
InnovationWell meeting Computational Biology Translational Medicine Systems Biology ADME Predictive ADME Predictive Toxicology Innovative Medicines Community of Practice workshop conference management executive Bryn Mawr Philadelphia Critical Path biomarkers metabolomics toxicology personalised medicine KM Life Sciences Pharma Drug Discovery Drug Safety Research and Development Drug Development Healthcare Innovation Knowledge Management events
During November I will be planning the program for the following InnovationWell workshop in Oxford (cross-industry sector) and InterAction Meeting in Bryn Mawr (life science/pharma/healthcare sector). Please contact me with your interests and proposals!
Knowledge Assessment & Performance Improvement of Collaborative Work and Innovation Activities
InnovationWell Workshop & Innovation Café, accompanied by pre-meeting
2 day hands-on workshop activities on collaborative systems and ELNs
20-22 June 2007, Oxford University, Oxford UK
Innovation in Life Science & Healthcare Research & Product Development
InnovationWell Community of Practice InterAction Meeting
15-18 October 2007, Bryn Mawr College, Philadelphia, PA, USA
Themes: FDA Critical Path Themes, Knowledge Management, Translational Research, Biomedical Informatics, Metabolomics, Biomarkers, Toxicology, Patient & Drug Safety
InnovationWell Gold membership
This entitles members to access InnovationWell meeting proceedings including audio, access to our Executive Insights reports from meeting and community of practice activities, and additional member discounts on meeting and training registration fees.
Download InnovationWell2007MembershipForm.pdf
Barry Hardy
Email: barry.hardy *[at]* douglasconnect.com
InnovationWell meeting workshop conference management executive Bryn Mawr Philadelphia Critical Pathbiomarkers metabolomics toxicology personalised medicine KM Life Sciences Pharma Drug Discovery Drug Safety Research and Development Drug Development Healthcare Innovation Knowledge Management events
Metabolomics is an FDA-identified Critical Path Opportunity (1) offering a toolkit which can be potentially applied to identification of safety biomarkers, diagnostic monitoring of patient response to drug treatment, lead optimization through toxicity assessment in non-clinical drug development, biochemical pathway studies in cells, animals and humans, patient stratification, and insights on and tracking of mechanisms associated with the onset of disease or following therapeutic intervention.
However, despite its above promise, the challenges in the complexity of the biological systems studies, the experimental spectroscopy methods used and the datasets generated has restricted to this point the full commercial application of metabolomics methods in the pharmaceutical industry and in healthcare.
The complexity of the interpretation of metabolomics data points to the need for improved data analytics and visualisation methods in decision making processes and situations (2). The importance of the value-added of the integration of metabolomics data with other proteomic and genomic data to provide a more integrated, accurate and broader view of the state of the biological system studied points to the importance of explicit knowledge management techniques in critical path areas of clinical research and drug development (3) to the application of semantic web, ontology and web service approaches (4) and to the adoption of these approaches in the day-to-day scientific research activity as supported by electronic laboratory notebooks and collaboration systems (5). It also points again to the importance of co-operation on the always difficult agreement area of the definition of standards and data integration.
I also find it quite interesting that two different fields (knowledge management and metabolomics) share a common critical concept: that of context. Context is critical in the human area of knowledge management and transfer in social ecosystems and its poor treatment a reason why many early IT and informatics approaches to knowledge management worked poorly. In the biological situation of a cell or animal, metabolomics provides the critical biochemical context and data to match it, and can do so in a dynamic way over time and can track perturbations in the behaviour of such a complex system.
Recent progress in the metabolomics field includes new advances in spectroscopic and statistical and analytical techniques that strengthen and expand the accuracy and scope of the analysis possible. But the progress also increasingly includes significant application experience which already has included a significant role in the 2005 Nobel Prize in Medicine award for assigning the causative role of H. pylori bacterium in peptic ulcers and gastritis, and more recently has been applied to patient stratification in Lou Gehrig’s disease, identification of off-targeted side effects for several drugs and new chemical entities, has been applied in diagnostic roles on serum samples of diabetics and non-diabetics, the development of biomarkers for prediction of drug-induced liver injury and to insight into toxic effects from urine analysis.
Richard Beger (FDA) has pointed out (6,7) that the development of NMR- based multi-dimensional quantitative spectrometric data-activity relationships (QSDAR) provides models which could be useful for estimating chemical toxicity, risk assessment of environmental contaminants and drug-lead identifications, and that such models of biological activity should be more objective and overcome some of the unreliabilities of traditional Quantitative Structure-Activity Relationship (QSAR) approaches (8). He also indicates that Metabolomics can play an important role in the creation of better evaluation tools and models for diseases, better identification and quantification of safety biomarkers, and improving the measurement of patient response. The voluntary submission of genomics data (VGDS) to the FDA is now accepting both proteomics and metabolomics data sets (9).
In response to such demand and interest, and in addition to significant activity in academic research, a number of companies including Metabolon, Leco, Blue Gnome, Bio-Rad and Chenomx are increasingly offering commercial solutions and services in metabolomics to industry.
I provide below a description of the presentation, discussion and workshop activity for the InnovationWell Session on Application of Metabolomics to Drug Discovery & Development which will take place on Wednesday 18th October ’06 at the InnovationWell meeting at Bryn Mawr. (Follow the Continuation…)
Barry Hardy
References
1. FDA Critical Path Opportunities Report, http://www.fda.gov/oc/initiatives/criticalpath
2. Decision Support in Drug Discovery & Development, http://barryhardy.blogs.com/theferryman/2006/09/decision_suppor.html
3. Knowledge Management in Translational Research, http://barryhardy.blogs.com/theferryman/2006/09/utilising_knowl.html
4. Semantic Web & Drug Development, http://www.innovationwell.net/COMTY_semweb/
5. KM in R&D and ELNs, http://www.innovationwell.net/COMTY_conferenceopenevent/
6. Richard D. Beger, Drug Discovery Today, Vol. 11, pp 429-435, May (2006).
7. R. D. Beger, D. A. Buzata, J.G. Wilkes, Drug Discovery Handbook, Ed. Shayne C. Gad, John Wiley & Sons, pp 227-285 (2005)
8. Predictive Toxicology, http://barryhardy.blogs.com/cheminfostream/2006/09/appyling_predic.html
9. FDA’s Critical Path Initiative: Opportunities for Metabolomics http://www.innovationwell.net/COMTY_mebegerr/
(continued…)
The FDA has identified the development of new biomarkers as one of the key opportunities to increase efficiency, predictability, and productivity in drug development. I provide below a description of the presentation, discussion and workshop activity for the session on Biomarker Discovery & Applications in Drug Development which will take place on Thursday 19th October ’06 at the InnovationWell meeting at Bryn Mawr.
The session on the application of biomarkers in drug development will explore new advances and challenges in this area and will include a keynote from Keith Elliston, CEO (Genstruct), with Zentam Tsuchihashi (BMS) discussing Biomarker Roles in Tumor Immunotherapy, Darius Dziuda (CCSU) will cover the topic of Multivariate BioMarkers, Michael Jones (Novartis) will discuss Proteomics applications whereas Bernd Bonnekoh (Otto-von-Guericke University) and Ansgar J. Pommer (SkinSysTec) will provide perspectives for Multi Epitope Ligand Kartography (MELK) and skin disease applications. This latter work is being published in Nature Biotechnlogy and is featured on its mid-October cover.
Full abstracts are provided below.
Barry Hardy
(continued…)
Continue reading "Biomarker Discovery & Applications in Drug Development" »
The final program and agenda for our 4 Day joint InnovationWell and eCheminfo Community of Practice Meeting on the themes of Innovation in Life Science & Healthcare Research & Product Development and Latest Advances in Drug Discovery & Development is now available and provided below. The meetings will take place at Bryn Mawr College, Philadelphia, USA, 16-19 October 2006. Program brochures may also be downloaded here:
InnovationWell Program Brochure on Innovation in Life Science & Healthcare Research & Product Development (Autumn 2006):
eCheminfo Program Brochure on Latest Advances in Drug Discovery & Development (Autumn 2006):
Download eChemProgramBrynMawr06-web1a4.PDF
Updates & Abstracts will be located at: http://www.innovationwell.net/COMTY_conferenceprogram/
and http://www.echeminfo.com/COMTY_conferenceprogram/
PROGRAM AND AGENDA
Monday 16 October
07.30 Registration & Welcome Coffee Opens, Thomas Great Hall
InnovationWell InterAction Meeting Session, 09.00 – 13.00
Utilising Knowledge Management to increase R&D Productivity along Critical Paths
Chair: Michael Liebman (Windber Research Institute)
Delia Y. Wolf (Harvard Medical School), What a Quality Assurance Program can do to Facilitate Clinical Research and Development Process
Peter Gates (Johnson & Johnson PR&D), A Framework for Research Informatics
Jonathan Sheldon (InforSense), Building an Informatics Infrastructure for Translational Research
Duane Shugars (Concentia Digital), Why the “Top-Down Approach” to Knowledge and Content Management has failed the United Sates Intelligence Community – Implications for Healthcare Research
Jian Wang (Biofortis), Knowledge Management for Translational Research
Jeff Spitzner (Rescentris), Applying Knowledge Assessment Techniques to improving Productivity in Life Science Research
eCheminfo InterAction Meeting Session, 08.30 – 13.00
Structure-based Drug Design
Chair: Frank Hollinger (Locus Pharmaceuticals)
Erin Duffy (Rib-X), Structure-Based Drug Design Targeting Infectious Disease
Mike Malamas (Wyeth), Structure-Based Design of Estrogen Receptor-beta Selective Compounds
Frank Hollinger (Locus Pharmaceuticals), Harnessing the power of Structure Based Drug Design using a Fragment Based Approach
Debananda Das (National Cancer Institute), Structural Interactions of CCR5 with HIV-1 entry inhibitors
Max Cummings (Johnson & Johnson PR&D), Small Molecule Inhibitors of Protein-Protein Interactions
Jose Duca (Schering-Plough), Using ab initio calculations as routine tools to help design CDK2 inhibitors
Paul Labute (Chemical Computing Group), High Strain Energies of Bound Ligands
13.00 Lunch
InnovationWell Workshop Activity, 14.00-17.30
14.00-15.30
Carrying out an Onsite Audit and Self-assessment in Clinical Trial Management
Delia Y. Wolf (Harvard Medical School)
16.00-17.30
Knowledge Assessment in R&D – Impact on Project Management & Research Productivity
Barry Hardy (Douglas Connect) & Jeff Spitzner (Rescentris)
eCheminfo Workshop Activity, 14.00 – 18.00
14.00-15.30
Quantum Biochemistry Workflows, Lance Westerhoff (QuantumBio)
Fragment- and Structure-Based Drug Design, Zenon Konteatis and Jennifer L. Ludington (Locus Pharmaceuticals)
16.00-18.00
Advanced Techniques in Pharmacophore Perception and Successful Applications in Drug Design, Osman F. Güner (Turquoise Consulting)
Advances in Virtual Screening and Structure-based Drug Design
Hege Beard and Shashi Rao (Schrodinger)
Hypothesis generation from docking results using activity measurements, interaction fingerprints, clustering and 2D visualization methods
Alex Clark (Chemical Computing Group)
18.00 Drinks & BBQ
Tuesday 17 October
InnovationWell InterAction Meeting Session, 09.00 – 13.00
Decision Support for Research & Development
Peter Henstock (Pfizer), The Role of Systems Biology and Knowledge Management in Advancing Toxicology Knowledge in Big Pharma
Craig Liddell (Realtime Science), Advanced Technology in Support of Analytics in the Life Sciences
David Mosenkis (Spotfire), Case Studies in Using Interactive Visual Analytics to Accelerate Drug Development
Joel Hoffman (Insightful), Management Reporting of Clinical Trial Programs, Portfolios, and Studies: Managing Risks / Managing Projects
Dennis Underwood (Praxeon), Searching for Answers in Drug Development: The Game of Twenty Questions
eCheminfo InterAction Meeting Session, 09.00 – 13.00
Screening
Stan Young (National Institute of Statistical Sciences), Analysis of HTS data using Recursive Partitioning
John Irwin (UCSF), Investigating bias in Docking Screens with Target, Ligand and Decoy Benchmarking Sets
Deepak Bandyopadhyay (Johnson & Johnson PR&D), A new Self-organizing Algorithm for Molecular Alignment and Pharmacophore Development
Daryll Reid (SimBioSys), Virtual Ligand Screening with eHiTS
Neysa Nevins (GlaxoSmithKline Pharmaceuticals), A Critical Assessment of Docking Programs and Scoring Functions
William Douglas Figg (National Cancer Institute), Development of Angiogenesis Inhibitors - from Screening to the Clinic
InnovationWell Workshop Activity, 14.00-17.30
14.00 – 15.30
Electronic Laboratory Notebook Workshops
16.00 – 17.30
Applying Roadmap processes to the Clinical Trials Project Process, Joel Hoffman (Insightful)
Innovation Management in R&D – an Enterprizer Briefing and Case Study, Joseph Bitran (Enterprizer)
Using Interactive Visual Analytics to Accelerate Drug Development, David Mosenkis (Spotfire)
16.00-21.00 Open Event on Knowledge Management in R&D & ELNS
16.00 Electronic Laboratory Notebook Demonstrations
17.30 Open Seminars & Panel Discussion
19.30 Knowledge Café on Knowledge Management in R&D
20.30 Reception
eCheminfo Workshop Activity, 14.00-17.30
14.00 – 15.30
Applications of Filtering and Similarity in Virtual Screening
Paul Hawkins (OpenEye)
Docking and Screening
Darryl Reid (SimBioSys)
16.00 – 17.30
Roundtable Discussion on Virtual Screening & Docking Study
This session will discuss current virtual screening and docking methods and software, results of existing validation and comparison studies, and procedures for community of practice studies to be undertaken.
Wednesday 18 October
InnovationWell InterAction Meeting Session, 08.30 – 16.00
Application of Metabolomics to Drug Discovery & Development
Chair: George G. Harrigan (Monsanto)
George Harrigan (Monsanto), An Overview of Developments in Metabolomics Approaches
Rick Beger (NCTR, FDA), FDA's Critical Path Initiative: Opportunities for Metabolomics
Alvin Berger (Metabolon), Application of Metabolomics to Biomarker and Off-Target Side Effect Identification in Marketed Drugs and New Chemical Entities
Don Robertson (Pfizer), Uses and Abuses of Metabonomics in Pharmaceutical Preclinical Safety Assessment
Gregory Banik (Bio-RAD), Toward Diagnosis of Diabetes by NMR-based Metabolomics
Teresa Garret (Duke University), Identification of novel, minor lipids in total lipid extracts of Eschericia coli using Electrospray ionization mass spectrometry
Nick Haan (BlueGnome), Analysis of Metabolic Profiling Data - Combining the Strengths of NMR and MS
Susan Connor (Glaxo SmithKline), A Pharma Perspective on Metabolomics - the Opportunities and Realities
Laszlo Boros (SIDMAP), Tracer Substrate-based Metabolomics and the 2005 Nobel Prize award in Physiology & Medicine
Bruce Kristal (Cornell University), Serum Markers of Caloric Restriction
Oliver Fiehn (UC Davis Genome Center), Standards in Reporting Initiative
Eric Nemec (Leco Corporation), Studies of Drug-Induced Liver Injury using Comprehensive 2D Gas Chromatography with Time-of-Flight Detection
eCheminfo InterAction Meeting Session, 09.00 – 13.00
Bench Scientists’ & Modellers’ Discussions on Discovery Tools & Modeling
In this session a panel of experimental and computational chemists will discuss their experiences in using computational modeling methods in drug discovery. They will discuss where the methods and software are having success, and where current methods are not yet meeting their needs, are failing or have challenges or complications. Short presentations on drug discovery experiences will be used to seed discussion of cheminformatics-driven medicinal chemistry and lead optimization and conversations on where new developments could aid improvement in practice and tools.
Panel: Chris Cooper (BMS), James Arnold (AstraZeneca), Phil Edwards (AstraZeneca), Pete Connolly (Johnson & Johnson PRD), Victor Lobanov (Johnson & Johnson PRD), Jim Wikel (Coalesix)
InnovationWell Workshop Activity, 16.30-18.00
NMR-based Positional Isotopomer Analysis in Metabolomics
Andrew N. Lane (JG Brown Cancer Center, U. Louisville)
Linking Metabolic Profiles to Biological Outcome
S. Stanley Young (National Institute of Statistical Sciences)
Understanding Metabolomics Mixtures with Principal Components Analysis
Gregory Banik (Bio-RAD)
eCheminfo Workshop Activity, 14.00-17.30
14.00 – 15.30
in silico Technology in Drug Discovery and Development
Michael B. Bolger (Simulations Plus and USC School of Pharmacy)
Using Physicochemical Property Predictions to Overcome ADME Concerns at Lead Optimization
Sanji Bhal and Karim Kassam (ACD/Labs)
16.00 – 17.30
Machine Intelligence in the Design of New Biologically Active Chemicals
Gilles Klopman (Multicase)
Challenges of ADME/Tox Prediction
Bob Clark (Tripos)
18.00 Poster Session, Drinks and BBQ
Thursday 19 October
InnovationWell InterAction Meeting Session, 09.00 – 13.00
Biomarker Discovery & Applications in Drug Development
Keith Elliston (Genstruct), Harnessing the Power of Systems Biology – Delivering Mechanism-of-Action and Biomarkers in Drug Development
Zentam Tsuchihashi (Bristol-MyersSquibb), Many Layers of Biomarker Roles in Tumor Immunotherapy
Darius Dziuda (Central Connecticut State University), Multivariate Biomarkers Discovery
Michael Jones (Novartis), Application of Proteomics to Biomarker Discovery
Bernd Bonnekoh, (Otto-von-Guericke-University), Perspectives for Multi Epitope Ligand Kartography (MELK) for Detection of Diagnostic and Therapeutic Biomarkers in Skin Diseases, Allergology and Beyond
eCheminfo InterAction Meeting Session, 09.00 – 16.00
Predictive Toxicology
Chair: Curt Breneman (Rensselaer Polytechnic Institute)
KEYNOTE: Tudor Oprea (Univ. New Mexico), The Physical basis for the Rule of Five
Navita Mallalieu (Roche Pharmaceuticals), A Roadmap for Integrating Modelling & Simulation in Pre-Clinical DMPK Research
Alex Tropsha (UNC), The Statistical Significance vs. Mechanistic Interpretation of ADME/tox models
Curt Breneman (Rensselaer Polytechnic Institute), Predictive ADME : How Do I Know if my Predictions will be Useful?
Sanji Bhal & Karim Kassam (ACD/Labs), An in silico Approach to Reduce the Burdens of Lead Discovery and Optimization
Michael B. Bolger (Simulations Plus and USC School of Pharmacy), Integration of Early ADME using Property Estimation and PBPK Simulation
Bob Clark (Tripos), The "Structures" in Structure-Activity Relationships
Gilles Klopman (Multicase), Machine Intelligence in the Design of New Biologically Active Chemicals
InnovationWell Workshop Activity, 14.00-16.00
Ansgar J. Pommer (SkinSysTec), Analyzing in-situ Proteomics by Multi Epitope Ligand Kartography (MELK) for Detection of Diagnostic and Therapeutic Biomarkers
InnovationWell meeting workshop conference management executive Bryn Mawr Philadelphia Critical Pathbiomarkers metabolomics toxicology personalised medicine KM Life Sciences Pharma Drug DiscoveryResearch and Development Drug Development Healthcare Innovation Knowledge Management events
At our InnovationWell Community of Practice Autumn Meeting on Innovation in Life Science & Healthcare Research & Product Development (16-19 October 2006, Bryn Mawr, Philadelphia) we will be concentrating on themes of relevance to FDA’s Critical Path initiative integrated into our ongoing themes of innovation and knowledge management in life science and healthcare product development and safety. The themes of knowledge management in clinical and translational research, decision support for R&D, Metabolomics, Predictive Toxicology and Biomarkers & Systems Biology approaches will be covered in four days of InterAction Meeting program sessions. In addition to morning presentations and panel discussions, workshops will run each afternoon expanding on discussions of topics, methods and practices, with bbq, social activity and poster sessions running on campus during the evenings.
Michael Liebman (Windber Research Institute) will chair a program examining the application of Knowledge Management techniques to increase R&D Productivity along Critical Paths in clinical and translational research and will be joined by Delia Y. Wolf (Harvard Medical School), Peter Gates (Johnson & Johnson PR&D), Jonathan Sheldon (InforSense), Duane Shugars (Concentia Digital), Jian Wang (Biofortis), and Jeff Spitzner (Rescentris).
The Decision Support for Research & Development will examine the application of knowledge and risk management, systems biology, analytics, and new technologies in improving productivity and decision making in R&D, clinical research and development. Presenters include Peter Henstock (Pfizer), Craig Liddell (Realtime Science), David Mosenkis (Spotfire), Joel Hoffman (IntraSphere), and Dennis Underwood (Praxeon).
A Metabolomics in Discovery & Development Day is being chaired by George Harrigan (Monsanto) and co-sponsored by the Metabolomics Society and includes presentations and workshops from Rick Beger (NCTR, FDA), Alvin Berger (Metabolon), Don Robertson (Pfizer), Gregory Banik (Bio-RAD), Teresa Garret (Duke University), Susan Connor (Glaxo SmithKline), Laszlo Boros (SIDMAP), Bruce Kristal (Cornell University), Stanley Young (NISS) and Andrew Lane (JG Brown Cancer Center, U. Louisville).
The FDA has identified the development of new biomarkers as one of the key opportunities to increase efficiency, predictability, and productivity in drug development. A session on the application of Biomarkers in Drug Development will explore new advances and challenges in this area and will include a keynote from Keith Elliston, CEO (Genstruct), with Zentam Tsuchihashi (BMS) discussing Biomarker Roles in Tumor Immunotherapy, while Darius Dziuda (CCSU) will cover the topic of Multivariate Biomarkers.
The Pedictive Toxicology session brings together leading ADME & Tox experts and includes a Keynote from Tudor Oprea and seminars from Navita Mallalieu (Roche), Alex Tropsha (UNC), Curt Breneman (RPI), Karim Kassam (ACD/Labs), Michael Bolger (USC School of Pharmacy), Bob Clark (Tripos), and Gilles Klopman (Multicase).
The program also includes eCheminfo Drug Discovery sessions on Structure-based Drug Design, Screening, and Medicinal Chemistry, which are also available to all registrants to attend. (http://www.echeminfo.com/COMTY_conferences/)
Program and schedule information can be viewed atPlease address any questions related to the conference, exhibition or workshop program to Dr. Barry Hardy, InnovationWell Community of Practice Manager, +41 61 851 0170, barry.hardy [at] douglasconnect.com. Registration enquiries should be directed to innovationwell [at] douglasconnect.com
Barry Hardy
InnovationWell meeting workshop conference management executive Bryn Mawr Philadelphia Critical Pathbiomarkers metabolomics toxicology personalised medicine KM Life Sciences Pharma Drug DiscoveryResearch and Development Drug Development Healthcare Innovation Knowledge Management events
Recent Comments